<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137331</url>
  </required_header>
  <id_info>
    <org_study_id>K301-I</org_study_id>
    <nct_id>NCT01137331</nct_id>
  </id_info>
  <brief_title>K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp</brief_title>
  <official_title>A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moberg Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moberg Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seborrhoeic eczema (SE) is a chronic, inflammatory skin disorder confined to areas of the
      head and trunk where sebaceous glands are most prominent. The severity varies from mild
      dandruff to exfoliative erythroderma that ranges from mild, patchy scaling to widespread, and
      thick, adherent crusts. The worldwide prevalence of SE is 3-5%, although dandruff, the
      mildest form of the disorder affects up to 15-20% of the population.

      In this multicentre, randomised, double-blind, placebo-controlled phase III study, adult SE
      patients are treated once daily for 4 weeks. The population for this study is patients with
      mild to moderate SE.

      The primary endpoint for this study is the efficacy of K301 compared to placebo which was
      based on the sum score for erythema and desquamation after 4 weeks of daily application.
      Secondary endpoints are to evaluate safety and tolerability as well as efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythema and desquamation scores</measure>
    <time_frame>Week 4</time_frame>
    <description>The sum of erythema and desquamation scores at Week 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema and desquamation scores</measure>
    <time_frame>Week 2</time_frame>
    <description>The sum of erythema and desquamation scores at Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>Erythema score at Week 2 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desquamation score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>Desquamation score at Week 2 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's global evaluation</measure>
    <time_frame>Week 4</time_frame>
    <description>Investigator's global evaluation at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global evaluation</measure>
    <time_frame>Week 4</time_frame>
    <description>Patient's global evaluation at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus/burning score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>Patient's pruritus/burning score at Week 2 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dandruff score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>Patient's dandruff score at Week 2 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>Proportion of responders at Week 2 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Weeks 2, 4 and 5</time_frame>
    <description>Adverse events classified by body system and preferred term</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Seborrhoeic Eczema of the Scalp</condition>
  <arm_group>
    <arm_group_label>K301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K301</intervention_name>
    <description>Liquid- applied once daily prior to bed</description>
    <arm_group_label>K301</arm_group_label>
    <other_name>K40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Liquid- applied once daily prior to bed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female (including fertile women)

          -  18-70 years of age

          -  Seborrhoeic eczema of the scalp for at least 2 months

          -  Presenting erythema and desquamation of mild to moderate intensity

          -  Signed written informed consent

        Exclusion Criteria:

          -  Seborrhoeic eczema or any other cutaneous disease of the face or scalp requiring a
             specific topical treatment (corticosteroids, antifungals, selenium sulphide,
             antibiotics, retinoids, benzoyl peroxide or a-hydroxyacids) during the previous 15
             days

          -  Oral treatment with cyclines, lithium, antifungals or inhaled corticosteroids during
             the previous month

          -  Use of systemic corticosteroids and retinoids during the previous 2 months

          -  Seborrhoeic eczema associated with Parkinson's disease or HIV infection

          -  Current or any history of ear, nose, and throat carcinoma

          -  Current or any history of severe concomitant disease according to Investigator's
             judgement

          -  Allergy to any of the tested treatment components

          -  Subject who has been previously enrolled in the phase II study K40-3 investigating
             Kaprolac® K40
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Åke Svensson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudkliniken UMAS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Läkarhuset Farsta Centrum</name>
      <address>
        <city>Farsta</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrumläkarna</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kristinelundskliniken Hudläkarmottagningen</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Me3plus clinical trials</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hedgrindhälsan AB</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudmottagningen</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Familjehälsan</name>
      <address>
        <city>Hofors</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Din doktor i Stockholm AB</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fruängens Läkarhus</name>
      <address>
        <city>Hägersten</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio Cityklinik</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limhamns Läkargrupp- Tärnan</name>
      <address>
        <city>Limhamn</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudläkarna i Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center för Läkemedelsprövningar</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudkliniken UMAS</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Möllevångens Husläkargrupp</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjortens VC</name>
      <address>
        <city>Trollhättan</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VC Silentzvägen Praktikertjänst</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hälsojouren</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Uppsala</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kjell Rensfeldt MD</name_title>
    <organization>Moberg Derma AB</organization>
  </responsible_party>
  <keyword>seborrhoeic eczema</keyword>
  <keyword>scalp</keyword>
  <keyword>dandruff</keyword>
  <keyword>K301</keyword>
  <keyword>K40</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

